ライフサイエンスコーパス: severe sepsis

1 al mortality among transferred patients with severe sepsis.

2 bacteria (GNBs) are common pathogens causing severe sepsis.

3 n-hospital mortality than did either SIRS or severe sepsis.

4 Vitamin D deficiency is common in severe sepsis.

5 antibiotics in critically ill patients with severe sepsis.

6 quential Organ Failure Assessment score, and severe sepsis.

7 an intervention that may improve outcomes in severe sepsis.

8 chers recruited a total of 632 patients with severe sepsis.

9 h, quality improvement, and health policy in severe sepsis.

10 ong children surviving hospitalizations with severe sepsis.

11 dition to standard of care, in patients with severe sepsis.

12 care for the patient after their episode of severe sepsis.

13 ty in critically ill patients with trauma or severe sepsis.

14 sis; impact on caregivers; and support after severe sepsis.

15 ired severe sepsis and healthcare-associated severe sepsis.

16 y to trials of acute respiratory failure and severe sepsis.

17 should be aware of this important sequela of severe sepsis.

18 of ICU and hospital stay increased with more severe sepsis.

19 considered to be patients at risk of having severe sepsis.

20 as given via i.v. catheter to pigs to induce severe sepsis.

21 % CI, 3.8-10.3) vs 3.5 (95% CI, 2.2-5.5) for severe sepsis.

22 eated in an external acute care hospital for severe sepsis.

23 lanced fluids for resuscitation in pediatric severe sepsis.

24 PICU patients diagnosed with severe sepsis.

25 gh dose in older adults, but not during more severe sepsis.

26 severe sepsis (25.9%), and hospital-acquired severe sepsis (11.3%) cases.

27 (50.3% vs 36.9%), dialysis (19.4% vs 10.3%), severe sepsis (20.3% vs 10.3%), and septic shock (33.5%

28 severe sepsis (62.8%), healthcare-associated severe sepsis (25.9%), and hospital-acquired severe seps

29 son of Eritoran and placebo in patients with Severe Sepsis, 580 patients had a quality of life measur

30 8.3 per 1,000 person-years) and 1,151 first severe sepsis (6.2 per 1,000 person-years) events.

31 hospitalizations included community-acquired severe sepsis (62.8%), healthcare-associated severe seps

32 with vs those without SOT (5.5% vs 9.4% for severe sepsis; 8.7% vs 12.7% for sepsis).

33 9th Edition, Clinical Modification codes for severe sepsis (995.92) and septic shock (785.52) identif

34 odification diagnosis of septicemia (038.x), severe sepsis (995.92), or septic shock (785.52), as wel

35 Severe sepsis, a systemic inflammatory response to infec

36 ociated severe sepsis, and hospital-acquired severe sepsis, adjusted hospital mortality, length of ho

37 In patients with severe sepsis, admission secretoneurin levels (logarithm

38 dent predictor of mortality in patients with severe sepsis, although its influence on mortality decli

39 In severe sepsis, an extracorporeal treatment which modulat

40 (95% confidence interval [CI], .79-.87) for severe sepsis and 0.78 (95% CI, .73-.84) for sepsis.

41 is a frequent complication in patients with severe sepsis and can worsen the prognosis.

42 utilization than both healthcare-associated severe sepsis and community-acquired severe sepsis, with

43 asma F2-isoprostanes, in adult patients with severe sepsis and detectable plasma cell-free hemoglobin

44 In adults with severe sepsis and detectable plasma cell-free hemoglobin

45 splant recipients are more likely to develop severe sepsis and die following a severe sepsis episode

46 resource utilization than community-acquired severe sepsis and healthcare-associated severe sepsis.

47 ional cohort of critically ill children with severe sepsis and high mortality rates, septic acute kid

48 n outpatient setting, and (4) infection with severe sepsis and managed in an inpatient setting with i

49 th reduced 28-day mortality in patients with severe sepsis and may even be harmful.

50 son of Eritoran and placebo in patients with Severe Sepsis and PROWESS-SHOCK, respectively).

51 son of Eritoran and placebo in patients with Severe Sepsis and PROWESS-SHOCK, the average age of pati

52 Among hospitalizations for severe sepsis and sepsis, in-hospital mortality was lowe

53 ment a machine learning algorithm to predict severe sepsis and septic shock and evaluate the impact o

54 We searched for terms related to severe sepsis and septic shock and terms related to poly

55 Children with severe sepsis and septic shock are best identified in th

56 Severe sepsis and septic shock are life-threatening cond

57 Sepsis, severe sepsis and septic shock are the main cause of mor

58 rance coverage and outcomes in patients with severe sepsis and septic shock as a result of the full i

59 nt of IV fluid administered to patients with severe sepsis and septic shock compared with usual care.

60 pact of a quality improvement initiative for severe sepsis and septic shock focused on the resuscitat

61 nfections remain the most important cause of severe sepsis and septic shock following splenectomy.

62 atment may reduce mortality in patients with severe sepsis and septic shock in specific disease sever

63 isticated epidemiologic studies of pediatric severe sepsis and septic shock in this large, multicente

64 Consecutive sample of all severe sepsis and septic shock patients (defined: infect

65 ater than or equal to one bundle element for severe sepsis and septic shock patients.

66 ere was an increase in insured patients with severe sepsis and septic shock post Affordable Care Act.

67 Patients with severe sepsis and septic shock treated between 2009 and

68 rtality among a small group of patients with severe sepsis and septic shock treated with hydrocortiso

69 The incidence of severe sepsis and septic shock was 9.7%.

70 esis of sepsis and its spectrum of diseases (severe sepsis and septic shock), which are leading cause

71 nd AdrenOSS-1 (Adrenomedullin and Outcome in Severe Sepsis and Septic Shock-1) enrolled 583 septic pa

72 n B hemoperfusion treatment in patients with severe sepsis and septic shock.

73 age or within 1 hour of shock recognition in severe sepsis and septic shock.

74 t the lactate concentration in patients with severe sepsis and septic shock.

75 and may decrease mortality in patients with severe sepsis and septic shock.

76 f antibiotic administration and mortality in severe sepsis and septic shock.

77 itation strategy is better for patients with severe sepsis and septic shock.

78 igh specificity, the impending occurrence of severe sepsis and septic shock.

79 database using explicit diagnosis codes for severe sepsis and septic shock.

80 adult medical and surgical ICU patients with severe sepsis and septic shock.

81 sion treatment on mortality in patients with severe sepsis and septic shock.

82 th normal blood lactate concentration during severe sepsis and septic shock: survival (p = 0.03) and

83 population incidence estimates of sepsis and severe sepsis and used negative binomial regression to a

84 population incidence estimates of sepsis and severe sepsis and used negative binomial regression to a

85 s greater than or equal to 18 years old with severe sepsis and/or septic shock and antimicrobial admi

86 Patients with severe sepsis and/or septic shock.

87 epsis, 0.4% (95% CI, 0.1-0.8%; P = 0.02) for severe sepsis, and 1.8% (95% CI, 0.8-3.0%; P = 0.001) fo

88 ere admitted with sepsis, 1,071 (62.5%) with severe sepsis, and 21 (1.2%) with septic shock.

89 s at risk (95% CI, 430-485) in patients with severe sepsis, and 9/100,000 person-years at risk (95% C

90 cquired severe sepsis, healthcare-associated severe sepsis, and hospital-acquired severe sepsis hospi

91 cquired severe sepsis, healthcare-associated severe sepsis, and hospital-acquired severe sepsis, adju

92 ess caused by diverse etiologies, especially severe sepsis, and observational studies have linked CMV

93 40% (95% CI, 36-44) in patients with sepsis, severe sepsis, and septic shock, respectively.

94 emic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.

95 d safety of heparin in patients with sepsis, severe sepsis, and septic shock.

96 gh: for septic shock, approximately 60%; for severe sepsis, approximately 36%; for sepsis attributed

97 To determine whether sepsis and severe sepsis are associated with vitamin D deficiency a

98 medical emergency department with sepsis and severe sepsis are more frequent than previously reported

99 onal clinical trials targeting children with severe sepsis are warranted.

100 frequent medical condition that can trigger severe sepsis as a life-threatening complication.

101 Patients younger than 18 years of age with severe sepsis as defined by consensus criteria were incl

102 We defined healthcare-associated severe sepsis as severe sepsis hospitalizations with an

103 We defined hospital-acquired severe sepsis as severe sepsis patients where the docume

104 had blood cultures ordered and patients with severe sepsis, as defined by concomitant International C

105 mortality probability and the development of severe, sepsis-associated AKI on Day 3 (D(3) SA-AKI) in

106 annual incidence of septicemia, sepsis, and severe sepsis at 2 academic hospitals from 2003 to 2012

107 0 days, 66.9% had an infection and 40.3% had severe sepsis at readmission.

108 Compared with controls, in severe sepsis, baseline plasma total cortisol was elevat

109 tem failure to identify hospitalizations for severe sepsis between 2000 and 2008.

110 muscle fiber atrophy develops in response to severe sepsis, but it is unclear as to how the proteolyt

111 variation between hospitals in their care of severe sepsis, but little information on whether this va

112 awareness of diagnosis and understanding of severe sepsis by patients and caregivers and difficultie

113 hether hospital and regional organization of severe sepsis care is associated with meaningful differe

114 ssociations bolster arguments to regionalize severe sepsis care, an approach that may necessitate int

115 iations between quintiles of annual hospital severe sepsis case volume for the receiving hospital and

116 e to a care facility, higher hospital annual severe sepsis case volume, and higher hospital sepsis mo

117 predictors of failure to measure lactates in severe sepsis cases in 2013.

118 CI, 98-226; tau = 0.99) for hospital-treated severe sepsis cases per 100,000 person-years.

119 is and 270 (95% CI, 176-412; tau = 0.60) for severe sepsis cases per 100,000 person-years.

120 ates of 31.5 million sepsis and 19.4 million severe sepsis cases, with potentially 5.3 million deaths

121 patients accounted for 13.2% of hospitalized severe sepsis cases.

122 Patients in one of three severe sepsis cohorts: 1) explicitly coded (n = 108,448)

123 e more likely to have comorbid pneumonia and severe sepsis.Conclusions: Noninvasive ventilation use d

124 HIV-infected patients with severe sepsis continue to suffer worse outcomes compared

125 son of Eritoran and placebo in patients with Severe Sepsis died or reported persistent problems at 1

126 hcare system, with one in 15 and one in five severe sepsis discharges readmitted within 7 and 30 days

127 Among 216,328 eligible severe sepsis discharges, there were 14,932 readmissions

128 poietic stem cell transplant recipients with severe sepsis during engraftment and subsequent admissio

129 tal mortality was 17% for sepsis and 26% for severe sepsis during this period.

130 Of 1,095 patients with severe sepsis enrolled, 165 (15%) were positive for HIV,

131 to develop severe sepsis and die following a severe sepsis episode than nontransplant patients.

132 psis Risk Score predicting future sepsis and severe sepsis events among community-dwelling adults.

133 need for two or more SIRS criteria to define severe sepsis excluded one in eight otherwise similar pa

134 itative analysis: awareness and knowledge of severe sepsis; experience of hospitalization, ongoing im

135 spitalizations, one in 20 children surviving severe sepsis experienced new device acquisition.

136 es, Ninth Revision (ICD-9) codes to identify severe sepsis, explicitly coded sepsis, and SOT (kidney,

137 resholds for managing patients with mild and severe sepsis from bacterial infections.

138 s have not differentiated community-acquired severe sepsis from healthcare-associated severe sepsis o

139 provided good-to-excellent discrimination of severe sepsis from severe SIRS (0.742-0.917 AUC of ROC c

140 Sixty-one patients with sepsis and severe sepsis from two large U.K. hospitals and 20 healt

141 Hospital-acquired severe sepsis had greater resource utilization than both

142 Patients with severe sepsis had significantly lower concentrations of

143 y injury requiring dialysis in patients with severe sepsis has also declined.

144 Prevalence of community-acquired severe sepsis, healthcare-associated severe sepsis, and

145 t to compare and contrast community-acquired severe sepsis, healthcare-associated severe sepsis, and

146 cerebral cortex, with those who experienced severe sepsis hospitalization being more than twice as l

147 known to result in dysbiosis and subsequent severe sepsis hospitalization that is not present for re

148 acquire new medical devices during pediatric severe sepsis hospitalization.

149 There were 903 816 severe sepsis hospitalizations (39 618 [4.4%] with SOT)

150 ampling weights, there were 55,624 pediatric severe sepsis hospitalizations and 1,585,194 all-cause n

151 Severe sepsis hospitalizations and organism-specific cau

152 New device acquisition was also higher in severe sepsis hospitalizations compared with matched non

153 ociated severe sepsis, and hospital-acquired severe sepsis hospitalizations in a national hospital sa

154 In this series, severe sepsis hospitalizations included community-acquir

155 red to all-cause pediatric hospitalizations, severe sepsis hospitalizations were eight-fold more like

156 The data for 5,033,257 severe sepsis hospitalizations were examined and reveale

157 fined healthcare-associated severe sepsis as severe sepsis hospitalizations with an infection present

158 Among 5,841 eligible pediatric severe sepsis hospitalizations with live discharge, 4,52

159 Among 18,210 pediatric severe sepsis hospitalizations, 1,024 (5.6%) underwent d

160 tionwide, all-payer cohort of U.S. pediatric severe sepsis hospitalizations, one in 20 children survi

161 ssociated severe sepsis or hospital-acquired severe sepsis hospitalizations.

162 rience of hospitalization, ongoing impact of severe sepsis; impact on caregivers; and support after s

163 uspected sepsis in only 65% of patients with severe sepsis in 2013.

164 of emergency department-attending sepsis and severe sepsis in adults was 1772 per 100 000 person-year

165 of emergency department-attending sepsis and severe sepsis in adults was 1772 per 100,000 person-year

166 examine factors associated with mortality of severe sepsis in hematopoietic stem cell transplant reci

167 The frequency of severe sepsis in hematopoietic stem cell transplant reci

168 he qSOFA performed better than both SIRS and severe sepsis in predicting in-hospital mortality, with

169 I]) were associated with increasing risk for severe sepsis in the 90 days after hospital discharge.

170 The underlying mechanisms of severe sepsis in the development of posttraumatic stress

171 Reports of outcomes of severe sepsis in this population are limited to data fro

172 Patients with severe sepsis-induced cardiogenic shock treated with VA-

173 Severe sepsis is a complex, resource intensive, and pote

174 Severe sepsis is a significant cause of healthcare use a

175 Severe sepsis is a significant cause of healthcare utili

176 ous infusion in critically ill patients with severe sepsis is associated with decreased hospital mort

177 ging from mild or asymptomatic infections to severe sepsis-like presentations or meningoencephalitis.

178 ling axis-driven myeloid proliferation and a severe sepsis-like syndrome.

179 We not only confirmed an overall decline in severe sepsis mortality from 1999 to 2008 but also ident

180 ternally validate, and externally validate a severe sepsis mortality prediction model and associated

181 This study explored organism-specific severe sepsis mortality trends from 1999 to 2008 in a la

182 cent studies have reported decreased overall severe sepsis mortality, but associations with organism

183 y unreported variations in organism-specific severe sepsis mortality.

184 Conclusions and Relevance: Among adults with severe sepsis not in septic shock, use of hydrocortisone

185 re the effects of dopamine or epinephrine in severe sepsis on 28-day mortality; secondary outcomes we

186 nical trial who lived independently prior to severe sepsis, one third had died and of those who survi

187 d mortality among patients hospitalized with severe sepsis or explicitly coded sepsis in 2012-2014.

188 red severe sepsis from healthcare-associated severe sepsis or hospital-acquired severe sepsis hospita

189 Among patients hospitalized for severe sepsis or sepsis, those with SOT had lower inpati

190 study period, 401 met consensus criteria for severe sepsis or septic shock (reference standard cohort

191 ification of Diseases, 9th Edition codes for severe sepsis or septic shock and a positive blood cultu

192 ardiac troponin T are frequently elevated in severe sepsis or septic shock and have relevant prognost

193 nit, 63% mechanically ventilated, and 42% in severe sepsis or septic shock at infection onset.

194 All adults treated with severe sepsis or septic shock between 2005 and 2014, usi

195 We enrolled 3,663 patients with severe sepsis or septic shock during three 4-month perio

196 Consecutive patients presenting with severe sepsis or septic shock from 2011 to 2013.

197 A total of 361,323 severe sepsis or septic shock hospital discharges were i

198 pectively enrolled consecutive patients with severe sepsis or septic shock in 2 intensive care units

199 6 hours of presentation in the management of severe sepsis or septic shock in this subset analysis of

200 Critically ill patients with severe sepsis or septic shock may need relatively high c

201 is, and those meeting consensus criteria for severe sepsis or septic shock on manual chart review wer

202 ion bundle, measuring serum lactate in adult severe sepsis or septic shock patients and its interacti

203 : 1) adult patients (n = 274) diagnosed with severe sepsis or septic shock per Sepsis-2 criteria from

204 Among patients with severe sepsis or septic shock receiving antimicrobials i

205 and shorter hospital stays in patients with severe sepsis or septic shock subsequently admitted to t

206 Two hundred sixty patients with severe sepsis or septic shock were included.

207 ours of hospital arrival with a diagnosis of severe sepsis or septic shock were included.

208 ICU adult patients with severe sepsis or septic shock who had Cl measured on ICU

209 tional, cohort study involving patients with severe sepsis or septic shock who received colistin was

210 Consecutive patients meeting criteria for severe sepsis or septic shock who were admitted to the I

211 Fifty-two patients with severe sepsis or septic shock with asplenia and 52 witho

212 in severely obese and nonobese patients with severe sepsis or septic shock.

213 25-hydroxyvitamin D levels in patients with severe sepsis or septic shock.

214 trospectively identified adult patients with severe sepsis or septic shock.

215 presentation for all patients with suspected severe sepsis or septic shock.

216 ased odds of PICU mortality in children with severe sepsis or septic shock.

217 rospective screening missed 66 patients with severe sepsis or septic shock.

218 th Revision, Clinical Modification codes for severe sepsis or septic shock.

219 iagnoses are present in 28% of children with severe sepsis or septic shock.

220 t between 2009 and 2015 for fluid-refractory severe sepsis or septic shock.

221 9th Revision, Clinical Modification code for severe sepsis or septic shock; 3,021 of these patients (

222 dmitted to intensive care units with sepsis, severe sepsis, or septic shock (as defined by the Intern

223 a, sepsis, organ dysfunction plus infection, severe sepsis, or septic shock.

224 s 0.65 (95% CI, 0.59-0.70) for both SIRS and severe sepsis (P < .001; incremental AUROC, 0.15; 95% CI

225 oad-spectrum antimicrobial administration in severe sepsis patients admitted through the emergency de

226 xclusive use of balanced fluids in pediatric severe sepsis patients for the first 72 hours of resusci

227 Hospitalized severe sepsis patients identified from National Health I

228 model Sepsis Alert with special attention to severe sepsis patients led to faster and more accurate a

229 e defined hospital-acquired severe sepsis as severe sepsis patients where the documented infection wa

230 We identified 3,929 severe sepsis patients, with overall mortality 12.8%.

231 Outcomes were severe sepsis point prevalence, therapies used, new or p

232 Severe sepsis poses a major burden on the U.S. healthcar

233 Greatest increases were seen for severe sepsis present on admission (3.8-fold increase).

234 Of 6,925 patients screened, 569 had severe sepsis (prevalence, 8.2%; 95% confidence interval

235 ther hydrocortisone therapy in patients with severe sepsis prevents the development of septic shock.

236 Severe sepsis readmission places a substantial burden on

237 Children with pediatric severe sepsis receiving balanced fluids for resuscitatio

238 Readmissions after severe sepsis remain understudied and could possibly sig

239 The consensus definition of severe sepsis requires suspected or proven infection, or

240 lock size stratified by site and presence of severe sepsis requiring vasopressors to receive either r

241 Sepsis Risk Score predict 10-year sepsis and severe sepsis risk among community-dwelling adults and m

242 The Sepsis Risk Score and Severe Sepsis Risk Score exhibited good discrimination (

243 rs in the best derived Sepsis Risk Score and Severe Sepsis Risk Score included chronic lung disease,

244 The Sepsis Risk Score and Severe Sepsis Risk Score predict 10-year sepsis and seve

245 nternally validate a Sepsis Risk Score and a Severe Sepsis Risk Score predicting future sepsis and se

246 Severe Sepsis Risk Score risk categories were very low (

247 Organ Failure Assessment score of 0.86, and Severe Sepsis Score of 0.82.

248 Sequential Organ Failure Assessment, and the Severe Sepsis Score were entered into a database.

249 erfusion, a key element in the management of severe sepsis, septic shock and in sports performance ev

250 admissions Database using explicit codes for severe sepsis, septic shock, or Dombrovskiy criteria (co

251 ervices adopted the Early Management Bundle, Severe Sepsis/Septic Shock (SEP-1) performance measure t

252 D) team dedicated to the early management of severe sepsis/septic shock (SS/SS) in Emergency Departme

253 obtained from 74 patients within 12 hours of severe sepsis/septic shock (SS/SS), and at set intervals

254 Changes of metabolites between sepsis and severe sepsis/septic shock also varied according to the

255 polyneuropathy/critical illness myopathy and severe sepsis/septic shock studies.

256 th Revision, Clinical Modification codes for severe sepsis/septic shock, 2) Martin approach, and 3) A

257 Within severe sepsis/septic shock, patients with bloodstream in

258 th community-acquired pneumonia in sepsis or severe sepsis/septic shock.

259 thy/critical illness myopathy and those with severe sepsis/septic shock.

260 and without asplenia and community-acquired severe sepsis/septic shock.

261 were linked to a total of 150,845 visits for severe sepsis/septic shock.

262 an 5 hours in antibiotic administration from severe sepsis/shock recognition.

263 used data from an international prospective severe sepsis study to elucidate functional outcomes of

264 l analysis of the Antibiotic Intervention in Severe Sepsis study, a Spanish national multicenter educ

265 vitro in milder infective events, but not in severe sepsis, supporting their potential utility as an

266 ciated cost and mortality of readmissions in severe sepsis survivors.

267 cohort of 40 children with clinically overt severe sepsis syndrome and 30 children immediately postc

268 The clinically overt severe sepsis syndrome children had confirmed or highly

269 rdiopulmonary bypass versus clinically overt severe sepsis syndrome descriptors included the followin

270 tcardiopulmonary bypass and clinically overt severe sepsis syndrome groups in children.

271 for 35 of 40 (87.5%) of the clinically overt severe sepsis syndrome patients and 29 of 30 (96.7%) of

272 tcardiopulmonary bypass and clinically overt severe sepsis syndrome patients by receiver operating ch

273 common readmission diagnoses after pediatric severe sepsis, the extent to which post-sepsis readmissi

274 In severe sepsis, there were no differences in plasma total

275 cripts are highly expressed in patients with severe sepsis; thus, suggesting that these pathways are

276 is associated with increased progression of severe sepsis to septic shock and increased mortality.

277 imicrobial is associated with progression of severe sepsis to septic shock.

278 odel that sepsis follows a continuum through severe sepsis to shock, and inadequate specificity and s

279 (weighted national estimate of 717,732) with severe sepsis transferred from another acute care hospit

280 ume-outcome associations among patients with severe sepsis transferred from another hospital.

281 nal disease, heart failure, sepsis severity (severe sepsis vs septic shock), obesity, Mortality in Em

282 nts admitted to the hospital with sepsis and severe sepsis was 23.7% (95% CI 22.7-24.7%) and 28.1% (9

283 nts admitted to the hospital with sepsis and severe sepsis was 23.7% (95% CI, 22.7-24.7%) and 28.1% (

284 The leading cause of severe sepsis was 51.5% Gram-negative bacteria, followed

285 Hospital-acquired severe sepsis was associated with both higher mortality

286 The task force concluded the term severe sepsis was redundant.

287 eta-analysis of critically ill patients with severe sepsis, we aimed to compare clinical outcomes of

288 Three cohorts of patients with severe sepsis were created: 1) International Classificat

289 poietic stem cell transplant recipients with severe sepsis were identified.

290 More than one in six children surviving severe sepsis were rehospitalized within 30 days, most c

291 n the intestine of animals with moderate and severe sepsis were significantly lower than that of sham

292 any, and it included 380 adult patients with severe sepsis who were not in septic shock.

293 ted to one of the participating centers with severe sepsis who were receiving antimicrobial therapy a

294 tal mortality was lowest among patients with severe sepsis who were transferred to high-volume hospit

295 andomized into controls, mild, moderate, and severe sepsis with equal number of animals in each group

296 The patient's condition was complicated by severe sepsis with positive blood culture Staphylococcus

297 ociated severe sepsis and community-acquired severe sepsis, with higher median length of hospital sta

298 pending on the patients' health prior to the severe sepsis, with the worst affected reporting lasting

299 a strong predictor of disease progression to severe sepsis within 72 hours.

300 efficacy of hydrocortisone in patients with severe sepsis without shock remains controversial.

301 ondition Category 27), 2.53 (2.49-2.56); and severe sepsis without shock, 2.48 (2.45-2.51).

302 of ventilation, and prevalence of cancer and severe sepsis, without objective data to substantiate or